Daphne Quimi
About Daphne Quimi
Daphne Quimi, 59, has served as an independent director at Amylyx Pharmaceuticals since June 2021 and is a Class III director with a term expiring at the 2027 annual meeting. She is a seasoned biopharma finance executive, formerly CFO of Amicus Therapeutics (2019–Aug 2023) and advisor to the CFO until March 2024, with prior roles at Bristol-Myers Squibb. She holds a B.S. in Accountancy from Monmouth University and an MBA from NYU Stern .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Amicus Therapeutics, Inc. | Chief Financial Officer | Jan 2019 – Aug 2023 | Led rare disease commercialization and global finance operations |
| Amicus Therapeutics, Inc. | Advisor to the CFO | Aug 2023 – Mar 2024 | Transitional advisory capacity |
| Bristol-Myers Squibb Company | Director of Consolidations & External Reporting | 2005 – 2007 | External reporting leadership |
External Roles
| Organization | Role | Since | Notes |
|---|---|---|---|
| Century Therapeutics, Inc. (Nasdaq: IPSC) | Director | Oct 2022 | Public company directorship |
| Chiesi Farmaceutici S.p.A. | Director | Jan 2025 | Private pharma board role |
Board Governance
- Independence: Board determined all directors except the Co-CEOs are independent under Nasdaq and SEC rules; Quimi is independent .
- Committee roles: Audit Committee Chair; Compensation Committee member. Audit members are independent; Quimi is designated the Audit Committee Financial Expert. Audit met 5 times in 2024; Compensation met 7 times in 2024 .
- Attendance: The full board met 16 times in 2024; each director attended at least 75% of board and applicable committee meetings. In 2023, the board met 13 times with ≥75% attendance by each director .
- Governance policies: Anti-hedging and anti-pledging policy; Compensation Recovery (clawback) policy adopted Oct 2, 2023 .
Fixed Compensation
| Metric | FY 2022 | FY 2024 | Notes |
|---|---|---|---|
| Board/Committee Cash Fees ($) | $58,589 | $72,500 | FY 2024 aligns with policy: Board member $45,000, Audit Chair $20,000, Compensation member $7,500 |
Cash retainers are set by the non-employee director compensation policy adopted and amended in 2023; Quimi’s FY 2024 fees reflect her roles as Audit Chair and Compensation member .
Performance Compensation
| Metric | FY 2022 | FY 2024 | Policy/Structure |
|---|---|---|---|
| Option Awards (Grant-Date Fair Value, $) | $293,500 | $27,704 | Annual equity grant: lesser of $285,000 FV or 25,000 options; Initial grant: lesser of $570,000 FV or 50,000 options |
| Options Held (Exercisable, #) | 38,830 | 115,351 | Year-end holdings (exercisable) |
| Options Held (Unexercisable, #) | 69,670 | 35,134 | Year-end holdings (unexercisable) |
Director equity is granted as stock options; vesting typically completes within one year for annual grants and pro-rates per policy. No RSUs for non-employee directors were outstanding at FY 2024 year-end .
Other Directorships & Interlocks
| Company | Relationship to AMLX | Potential Interlock/Conflict Notes |
|---|---|---|
| Century Therapeutics, Inc. (IPSC) | No related-party transactions disclosed | Monitor for future collaborations/transactions given biopharma domain overlap; none reported since Jan 1, 2023 |
| Chiesi Farmaceutici S.p.A. | No related-party transactions disclosed | Private company role; watch for supplier/customer relationships; none reported |
Expertise & Qualifications
- Financial expert: Audit Committee Financial Expert designation under SEC rules .
- Strategic finance and commercialization experience in rare diseases; senior roles at Amicus and Bristol-Myers Squibb .
- Formal education: B.S. in Accountancy; MBA (NYU Stern) .
Equity Ownership
| Metric | As of Apr 11, 2023 | As of Apr 11, 2025 |
|---|---|---|
| Beneficial Ownership (Total Shares) | 66,275 (options exercisable within 60 days) | 153,796 (5,000 common + 148,796 options exercisable within 60 days) |
| Ownership % of Outstanding | <1% (company disclosure) | <1% (company disclosure) |
| Anti-Hedging/Pledging Compliance | Policy prohibits hedging/pledging | Policy prohibits hedging/pledging |
Governance Assessment
-
Strengths
- Independent director with deep finance expertise; Audit Committee Chair and SEC-designated financial expert support robust financial oversight .
- Solid engagement: frequent committee meetings (Audit 5x; Compensation 7x in 2024) and ≥75% attendance; indicates active oversight .
- Alignment policies: Anti-hedging/pledging and clawback adopted Oct 2023 enhance investor protection .
- Ownership: Increased in-the-money/exercisable options and common share holding by 2025; supports skin-in-the-game (albeit <1%) .
-
Watch items
- Multi-board commitments (Century Therapeutics; Chiesi) could present time-allocation risks; monitor for potential related-party transactions or strategic overlaps—none disclosed since Jan 1, 2023 .
- Director equity is option-heavy; while standard, large variability in grant-date values (2022 vs 2024) merits monitoring for consistency with policy and market alignment .
-
Red flags
- None disclosed: No related-party transactions above threshold, no legal proceedings adverse to AMLX, and no pledging/hedging activities permitted .
Compensation Committee uses independent consultant Pearl Meyer; committee independence affirmed; no consultant conflicts identified .